Corporate governance > Leadership team
According to the Articles of Incorporation, Revenio Group Corporation shall have a President and CEO. The CEO’s task is to manage the operation of the Company in accordance with guidelines and rules laid out by the Board of Directors, and inform the Board of the development of the Company’s business operations and financial position. Additionally, the CEO is responsible for organizing the Company’s day-to-day management and to ensure that the Company’s asset management is arranged in a reliable way. The CEO is appointed by the Board of Directors, which also specifies the terms and conditions of the CEO’s employment in a written employment contract that has been approved by the Board of Directors. The contract also contains the financial benefits of the employment, such as severance pay and any other compensations. The CEO may not be elected as Chair of the Board of Directors.
Revenio Group's Leadership Team consists of the President & CEO, heads of various functions, and Managing Directors of the Group's subsidiaries.
In contrast to the Company’s statutory governing bodies, the duties of the Leadership Team are operational. The Leadership Team convenes at least once a month.
planning and monitoring investments;
preparing for and implementing corporate acquisitions;
preparing strategy proposals;
managing and monitoring daily business operations;
measures related to preparatory work for Board meetings.
Jouni started as CEO of Revenio Group Corporation and its' subsidiaries since May 18, 2020. Jouni has experience in international business as well as in the health technology and software businesses. Before joining Revenio, Jouni has worked as CEO at Innokas Medical Oy and Symbio Finland Oy and in executive positions at Nokia UK Ltd and Meridea Financial Software UK Ltd.
Mika has worked as R&D Direcotr of Icare Finland since September 2015. Mika has extensive experience in R&D. He has over 20 years of experience in international R&D operations, among others at Thermo Fisher Scientific and Vaisala. He was appointed a member of Revenio Group´s Management Team from 1 February, 2018.
Tomi has spent 20 years working in various managerial positions in international business and sales and marketing in the field of health technology. His former employers include Datex-Ohmeda, Spacelabs, Perlos and Medisize. His latest position was that of Hospital Division Director at Serres Oy. He was one of the forerunners who introduced the Medical IT business to Germany and Austria and has participated in numerous corporate acquisitions while employed by Datex-Ohmeda and Perlos. He was was appointed a member of Revenio Group’s Management Team starting from August 6, 2015.
Ari has been Operations Director of Icare Finland since September 2012. He has 20 years of experience of executive positions in production, purchasing and logistics in companies operating in national and international markets, such as Perlos and Ensto. He was appointed a member of Revenio Group’s Management Team from 1 June 2016.
Heli has held the position of QA Manager at Icare Finland since 2010. Previously Heli has worked as QA Manager at Plexpress Oy, as CTO at CTT Cancer Targeting Technologies Ltd and as Research Scientist at University of Helsinki, Haartman Institute. She was appointed a member of Revenio Group’s Management Team from 1 February, 2018.
Robin joined Revenio from the position of Symbio´s EMEA area CFO. Priot to this, Robin held several managerial positions in international corporations both in Finland and Canada. He has solid experience in various financial management roles. Robin was appointed CFO of Revenio Group Corporation on July 15, 2015 and has been a member of Revenio Group´s Management Team since August 6, 2015.
Giuliano Barbaro has spent 20 years working in various managerial positions in the field of diagnostic ophthalmology. He previously served as R&D manager at Nidek Technologies, a subsidiary of Nidek Co. and then contributed to the foundation of CenterVue, acting as the CEO in the early years and later on leading the R&D division. Giuliano was appointed a member of Revenio Group Corporation's Management Team from January 1, 2020.
Kate is the co-founder of Oculo. Before founding Oculo, Kate has worked in strategy, policy and advocacy with McKinsey & Company, the World Economic Forum’s Global Health Initiative, International AIDS Vaccine Initiative, and GlaxoSmithKline Biologicals. Kate serves on the Australian Independent Hospital Pricing Authority and the Australian Digital Health Agency’s Clinical and Technical Advisory Committee. Kate was appointed a member of Revenio Group Corporation’s Management Team from May 28, 2021.